Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk CEO Mike Doustdar announced that 1.5 million people in the U.S. are using compounded GLP-1 weight-loss drugs, which are cheaper alternatives to brand-name options like Wegovy. He emphasized that price, not safety, drives this trend. In response, Novo launched a daily oral version of Wegovy at $149 per month. Doustdar noted the need to rethink pricing strategies due to the rise of compounded drugs. Analysts have a Moderate Buy consensus on NVO stock, with an average price target of $54.67, indicating an 8.1% downside risk.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments